Eli Lilly partners with Hims and Hers for drug sales
Eli Lilly reached an agreement allowing Hims and Hers Health to sell its obesity treatments Zepbound and Foundayo directly on its platform. The telehealth company shares rose in premarket trading following the news.
Xurve View
Insights:
Xurve View
Eli Lilly & Co struck a deal to sell obesity drugs Zepbound and Foundayo directly on Hims & Hers Health Inc's platform, sending shares up 7% in premarket trading on Friday. The partnership puts Lilly on equal footing with Danish rival Novo Nordisk A/S-B in the telehealth market. The agreement expands patient access to branded weight-loss treatments following the telehealth company's exit from mass compounding.
